Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | MGMT | P16455 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458085 | 0.86 | MAPT (0.44) | MAPTTDP1CDK2CDK1CDK4 | |
| SCHEMBL5026853 | 0.76 | CDK2 (0.38) | MAPTCDK2CDK1CDK4CCNA2 | |
| SCHEMBL29693584 | 0.75 | CDK2 (0.41) | MAPTTDP1CDK2CDK1CDK4 | |
| SCHEMBL4160357 | 0.75 | CDK2 (0.52) | MAPTTDP1CDK2CDK1CDK4 | |
| SCHEMBL29473573 | 0.75 | CDK2 (0.52) | MAPTTDP1CDK2CDK1CDK4 | |
| SCHEMBL2745214 | 0.75 | CDK2 (0.41) | MAPTTDP1CDK2CDK1CDK4 | |
| SCHEMBL8990633 | 0.75 | CDK1 (0.47) | MAPTCDK2CDK1CCNA2CCNA1 | |
| SCHEMBL19398338 | 0.74 | MAPT (0.46) | MAPTTDP1 | |
| SCHEMBL6402248 | 0.72 | CDK2 (0.40) | MAPTCDK2CDK1CDK4CCNA2 | |
| SCHEMBL10441417 | 0.72 | CDK2 (0.38) | MAPTCDK2CDK1CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | MAPT 3520/4885TDP1 914/4885CDK2 440/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | MAPT 3520/4885TDP1 914/4885CDK2 440/4885 |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TLR7, C5, CD4 | MAPT 2673/4885TDP1 1142/4885CDK2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.